OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
OPKO HEALTH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 28, 2026
$1.61+0.08 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
OPKO HEALTH, INC. revenue by segment
By business segment
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics [Member] | $4.76M | -$12.95M | -$18.29M | $81.63M | -$18.16M | -$23.92M | -$21.68M | $58.54M | -$26.58M | -$34.40M | -$42.25M | -$29.08M | -126.2% |
| Pharmaceutical [Member] | $839.00K | -$29.68M | -$10.68M | -$24.19M | -$28.71M | -$34.77M | -$2.10M | -$32.20M | -$24.82M | -$27.68M | -$16.03M | -$25.38M | -102.9% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $74.55M | $72.19M | $71.09M | $95.24M | $101.10M | $102.84M | $103.11M | $121.27M | $129.40M | $126.89M | $124.18M | $131.68M | 45.6% | -26.3% |
| Intellectual Property and Other [Member] | $46.10M | $14.00M | – | $18.70M | $15.00M | $12.30M | – | $13.20M | $12.30M | – | – | – | 28.2% | +207.3% |
| Transfer of Intellectual Property and Other [Member] | $46.09M | $13.97M | $33.70M | $18.75M | $14.96M | $12.27M | $43.09M | $13.22M | $12.31M | $8.75M | $14.73M | $6.25M | 28.2% | +208.0% |
| Product [Member] | $42.94M | $38.04M | $43.66M | $37.68M | $40.74M | $34.84M | $37.44M | $39.14M | $40.49M | $38.05M | $43.00M | $40.67M | 26.3% | +5.4% |
| Rayaldee [Member] | $14.26M | $12.81M | $16.87M | $14.88M | $14.53M | $13.11M | $19.85M | $15.87M | $18.42M | $15.16M | $19.61M | $16.09M | 8.7% | -1.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $88.81M | $83.50M | $94.05M | $110.92M | $114.88M | $116.21M | $135.88M | $132.66M | $141.72M | $136.04M | $134.84M | $139.04M | 54.3% | -22.7% |
| Ireland | $41.66M | $9.68M | $22.10M | $12.08M | $11.74M | $5.48M | $17.82M | $11.51M | $9.84M | $9.22M | $20.22M | $8.65M | 25.5% | +254.8% |
| Chile | $16.43M | $14.87M | $17.48M | $14.36M | $16.00M | $14.53M | $15.98M | $16.58M | $17.60M | $14.89M | $16.06M | $16.93M | 10.0% | +2.7% |
| Spain | $8.45M | $8.05M | $7.22M | $6.34M | $6.72M | $6.44M | $6.81M | $6.30M | $5.87M | $5.66M | $7.09M | $4.35M | 5.2% | +25.7% |
| Mexico | $7.04M | $6.94M | $6.26M | $6.74M | $6.30M | $6.23M | $5.25M | $5.63M | $5.91M | $7.08M | $2.77M | $5.90M | 4.3% | +11.8% |
| Other Countries [Member] | $1.19M | $1.15M | $1.17M | $1.09M | $1.02M | $992.00K | $933.00K | $756.00K | $804.00K | $630.00K | $580.00K | $565.00K | 0.7% | +16.5% |
| Israel | $0 | $0 | $171.00K | $140.00K | $139.00K | $73.00K | $975.00K | $196.00K | $441.00K | $160.00K | $350.00K | $3.16M | 0.0% | -100.0% |
From the segment and revenue-disaggregation notes of Opko Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.